Clinical Research
Filter News
Found 147,660 articles
-
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
3/28/2024
GenFleet Therapeutics announced it has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to start a combination study of GFH009 and BRUKINSA® in a multicenter phase Ib/II trial treating diffuse large B cell lymphoma.
-
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
3/28/2024
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine.
-
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
3/28/2024
NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, announced it has entered into an agreement with Veranex, Inc. to assist with the development of the company’s next generation UroShield and PainShield products.
-
New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
3/28/2024
Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.
-
Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
3/28/2024
Twist Bioscience Corporation announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing.
-
Headlands Research Announces Fifth Research Site under Partnership with Pfizer to Improve Diversity in Clinical Trials
3/28/2024
Headlands Research, a leading multinational network of clinical trial sites, announced a fifth site, Headlands Research Orlando, as part of its partnership with Pfizer to create multiple clinical trial sites in areas with highly diverse demographics.
-
Mechanism Found to Determine which Memories Last
3/28/2024
Neuroscientists have established in recent decades the idea that some of each day's experiences are converted by the brain into permanent memories during sleep the same night.
-
Health economics and outcomes research (HEOR) is a critical but sometimes overlooked part of drug development. Decentralized trials now make it easy.
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
3/27/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.
-
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
3/27/2024
Ludwig Enterprises, Inc is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma, an incurable brain cancer.
-
Linear Health Sciences Publishes Whitepaper Examining IV Dislodgement
3/27/2024
Linear Health Sciences announced the publication of a new whitepaper on accidental dislodgement of IV catheter lines.
-
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
3/27/2024
argenx SE announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease, following the analysis of topline data from the Phase 2 RHO study.
-
Chemical Insights Research Institute Shares its Latest Research Findings on PFAS Associated with Consumer and Commercial Textiles
3/27/2024
Chemical Insights Research Institute of UL Research Institutes has released its first report on a multi-phase research study of per- and polyfluoroalkyl substances, commonly referred to as “forever chemicals,” associated with consumer and commercial textiles.
-
Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia
3/27/2024
Cantargia Cantargia reported on the progress in the upcoming phase Ib/IIa clinical trial investigating nadunolimab in up to 40 patients with acute myeloid leukemia or myelodysplastic syndrome.
-
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
3/27/2024
Algernon Pharmaceuticals Inc. is pleased to announce that it has closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 research program for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx.
-
Biosenta Announces Successful Launch of Bench Scale Production Plant and Exceeding Expectations of Tri-Filler(TM) Particle Encapsulation Technology
3/27/2024
Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - March 27, 2024) - Biosenta Inc. (CSE: ZRO) ("Biosenta" or the "Company") is pleased to announce a significant milestone in its technological and operational advancements with the successful construction and operation of a bench scale production plant.
-
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
3/26/2024
Telomir Pharmaceuticals, Inc. announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.
-
A Revolutionary Breakthrough in Biomedical Testing: AmeboGenesis Introduces Sustainable Amebocyte Production for LAL Testing to Detect Bacterial Contamination
3/26/2024
AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process.
-
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
3/26/2024
Actinium Pharmaceuticals, Inc. announced that the University of Texas Southwestern Medical Center will lead a clinical trial studying Actinium's Iomab-ACT, a targeted radiotherapy conditioning agent prior to patients receiving an FDA approved commercial CAR T-cell therapy.
-
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
3/26/2024
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Raul Torres's Lab at the University of Colorado School of Medicine.